Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)

Boehringer Ingelheim

Status: Completed

Conditions: Prostatic Hyperplasia

Treatments: Drug: Tamsulosin

Study type: Observational

Funder types: Industry

Identifiers

NCT02245503

527.40

Details and patient eligibility

About

The objectives of this post marketing surveillance study were to document the comorbidity and comedication during prescription of ALNA® (Tamsulosin) for patients with BPH (Benign Prostatic Hyperplasia).

Enrollment: 7,391 patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• Indication for the treatment with ALNA according to its summary of product characteristics (SPC)

Exclusion criteria

• Patients fulfilling one of the general or specific contraindications listed in the ALNA SPC, particularly patients with known hypersensitivities against tamsulosin hydrochloride or any other ingredient of the product, orthostatic dysregulation or severe liver insufficiency cannot be included in the study

Trial design

7,391 participants in 1 patient group

Benign prostatic hyperplasia

Description:

Patients with symptomatic BPH to whom ALNA was prescribed

Treatment:

Drug: Tamsulosin